Navigation Links
Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
Date:5/15/2008

PRINCETON, N.J., May 15 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported unaudited financial results for the second fiscal quarter ended March 31, 2008. Pharmasset reported a net loss attributable to common stockholders of $12.1 million, or ($0.57) per share for the quarter ended March 31, 2008, as compared to a net loss attributable to common stockholders of $1.7 million, or ($0.16) per share for the same period in 2007.

Revenues were $0.5 million and $5.5 million during the quarters ended March 31, 2008 and 2007, respectively. Revenues during each period reflect amortization of up-front and subsequent collaborative and license payments received from Roche previously recorded as deferred revenue of $0.5 million. Revenues from the year ago quarter also include a milestone payment of $5.0 million received pursuant to the Roche collaboration.

Total costs and expenses for the quarter ended March 31, 2008 were $12.8 million as compared to $7.3 million for the same period in 2007. The $5.5 million increase in total costs and expenses during the quarter ended March 31, 2008 was primarily due to a $2.9 million increase in Phase 3 registration clinical trial expenses for clevudine for the treatment of chronic hepatitis B virus (HBV) infection, a $1.2 million increase in compensation expense resulting from increased headcount and a $1.4 million increase in legal, insurance, audit and marketing expenses. Interest expense increased to $0.4 million during the quarter ended March 31, 2008 from $0.0 million in the quarter ended March 31, 2007. The increase was due to interest on the $10
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
2. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
3. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
4. Pharmassets Underwriters Release Shares from Lock-Up
5. Nephros Reports 2008 First Quarter Financial Results
6. PreMD Reports First Quarter Results
7. Lifeway Foods Reports Record 1st Quarter 2008 Results
8. Corgenix Reports Third Quarter Fiscal 2008 Financial Results
9. Tiens Biotech Group (USA) Reports First Quarter Results
10. Cardiogenesis Reports First Quarter 2008 Results
11. STEN Corp. Reports 2008 Second-Quarter Revenue of $4.3 Million and Improved Results From Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... September 20, 2014 Ticket Down ... tickets . This popular ticket exchange is offering their ... , The 2015 schedule of tours is beginning to fill ... announced their plans to hit the road, including 21-year-old pop ... announced the “Honeymoon Tour,” which will take her to 25 ...
(Date:9/20/2014)... 2014 The print component of ... of the Calgary Herald, with a circulation of ... 270,000. The digital component is distributed nationally through ... network of top news sites and partner outlets. ... visit http://www.worklifebalanceinfo.ca . , The publication features ...
(Date:9/20/2014)... festival season is coming soon. The high-end fashion designer BellasDress ... dresses . A lot of sophisticated women like its new ... promotion for its high quality clothes. Now, each of its ... to 71 percent off. , The company’s cocktail dress ... in many fashionable colors. Mary, the company’s sales manager, believes ...
(Date:9/20/2014)... 2014 iFitDress.com, the popular online supplier ... has recently unveiled its new collection of cocktail gowns. ... special offer on these new outfits; it intends to ... customers can now buy cheap cocktail dresses ... representative says, “We have extensive experience in the industry ...
(Date:9/20/2014)... 20, 2014 "As a nurse, patients always ... said an inventor from Tamaqua, Pa. "The reason that they ... backs of their chairs. My invention enables them to check ... Oxygen Sensor to make it easier to monitor the contents ... knows when the tank is low. It allows changeovers to ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Fashionable Cocktail Dresses Unveiled Online at iFitDress.com 2
... , , , ... leading provider of advanced clinical documentation software, workflow tools, consulting ... as Corporate Vice President of Marketing and Communications. Reporting ... with designing and implementing new marketing initiatives that blend the ...
... NEW ORLEANS, July 29 Smoothie King, the 1973 originator ... leading the way to making healthy alternatives and high-quality meal replacements available ... Consumers in Tokyo will be the first in Japan to enjoy the ... open in 2010. Japan makes sense as the latest Smoothie King market, ...
... HAIKOU CITY, China, July 29 /PRNewswire-Asia-FirstCall/ -- China ... develops,manufactures, and markets specialty pharmaceutical products in China, today,announced ... results on,Wednesday, August 12, 2009, before the market opens. ... a conference call at 8:00 am ET on August ...
... , SOUTH SAN FRANCISCO, Calif., July 29 ... biopharmaceutical company focused on innovative oncology therapies, today announced that ... to provide a corporate overview, including a discussion about the ... at two upcoming investor conferences: , , ...
... chemo, expert says , WEDNESDAY, July 29 (HealthDay News) ... tumors show promise, U.S. researchers report. , The nanoparticles ... fatty molecules that can be designed to carry a ... to control how long they remain in the bloodstream. ...
... , , DARIEN, Conn., July 29 ... Switch , a sparkling 100% juice, is expanding its availability into ... The Switch has added key retailers Tops, D,Agostinos, ... And the list of eager retailers keeps growing with Wegmans, Price ...
Cached Medicine News:Health News:Precyse Solutions Taps Former Siemens Executive to Lead New Marketing Organization 2Health News:Smoothie King Expansion Signals International Trend Toward Healthy Living 2Health News:Smoothie King Expansion Signals International Trend Toward Healthy Living 3Health News:China Pharma Holdings, Inc. to Report Second Quarter 2009 Financial Results on August 12, 2009 2Health News:Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August 2Health News:Scientists Test New Way to Get Drugs to Cancer Cells 2Health News:People Across the Country are Making The Switch! 2
(Date:9/20/2014)... The issue: Mylan Pharmaceuticals ULC Canada, in consultation with Health ... 0.4 mg/metered dose due to the product missing the "dip ... A missing "dip tube" could pose a potential problem ... may lead patients to believe they are receiving the nitroglycerin, ... receiving nitroglycerin could place them at risk for either a ...
(Date:9/19/2014)... , Sept. 19, 2014 Medical science ... relationships with key opinion leaders (KOLs) who can ... Despite the critical nature of the MSL function, ... including altering the landscape for creating and maintaining ... to research, the oversight responsibility for the MSL ...
(Date:9/19/2014)... , Sept. 19, 2014 Harwood Feffer LLP ... board of directors of PDL BioPharma, Inc. ("PDL" or ... the board has breached its fiduciary duties to shareholders ... September 16, 2014, the Company disclosed: "On September 11, ... accounting firm, Ernst & Young LLP ("EY"), that it ...
Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2Role of Medical Science Liaisons Shifting in Healthcare Industry 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... 2011 ,   EP ... of the Year Award at the European Mediscience,Awards, sponsored ... award, which honours clear and concise commentary in the,pharma ... research houses or specialist websites dedicated to,providing sharp, perceptive ...
... 24, 2011 New Phase 2 clinical trial data ... of Medicine show that patients with moderate to ... bardoxolone methyl for 52 weeks experienced a sustained improvement ... by estimated glomerular filtration rate (eGFR). The data were ...
Cached Medicine Technology:EP Vantage Wins Commentator of the Year Award at European Mediscience Awards 2011 2EP Vantage Wins Commentator of the Year Award at European Mediscience Awards 2011 3New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 2New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 3New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 4